Nectar's alopecia drug mispriced on safety edge
The bull case argued for Nectar: its alopecia areata drug, while slower-acting and less efficacious than JAK inhibitors, is dramatically safer and could become the first-line treatment in a multi-billion dollar market.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.